Loading...
Defines medical necessity criteria, documentation, prior authorization, coverage stance, and billing guidance for PathFinderTG molecular/topographic genotyping (eg PancraGEN, BarreGEN) when used as a second-line diagnostic adjunct for pancreatic cyst fluid, Barrett esophagus, and solid pancreaticobiliary lesions for Medicare Advantage and Commercial products.
No material clinical or coverage changes identified in this update.
Overview: PathFinderTG is a topographic genotyping (molecular anatomic pathology) platform that integrates microscopic anatomic pathology microdissection with molecular analysis to increase tumor cell yield from small or minute specimens. It is positioned as an occasional second-line diagnostic adjunct when first-line analyses are inconclusive for pancreatic cysts, Barrett esophagus, or solid pancreaticobiliary lesions. Coverage stance is mixed: the policy defines specific medical necessity criteria for use in pancreatic cyst fluid evaluation (primary covered indication) while other indications are not covered. Regulatory status: PathFinderTG is offered as a laboratory-developed test (LDT) under CLIA; the U.S. Food and Drug Administration has not required regulatory review of this test.
Medicare Advantage Plans and Commercial Products - Covered Indication (pancreatic cyst evaluation)
ALL of the following
Evidence of prior first-line diagnostics (ONE or more of the following)
Medicare Advantage Plans and Commercial Products - Not Covered Indications
All other PathfinderTG indications are not covered due to insufficient data on analytical and/or clinical validity.
ANY of the following
All other PathfinderTG indications are not covered due to insufficient data on analytical and/or clinical validity. Uses of PathfinderTG other than pancreatic cyst fluid evaluation (for example, for other diagnostic indications such as Barrett esophagus or solid pancreaticobiliary lesions) are considered not covered.
| 84999 | Unlisted chemistry procedure (suggested unlisted CPT code when no specific code exists) |
| 81479 | Unlisted molecular pathology procedure (suggested unlisted CPT code when no specific code exists) |
Prior authorization required for Medicare Advantage
Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products and must be obtained via the payer's online tool for participating providers.
Medical record documentation requirements
Maintain legible medical record pages with patient identification and provider signature; documentation must support the selected ICD-10-CM and CPT/HCPCS codes and the medical necessity per policy, including why first-line diagnostics were insufficient.
Background: Topographic genotyping (PathFinderTG) combines microscopic identification and microdissection of areas of interest with molecular testing to increase tumor cell yield and may permit pathologic diagnosis when first-line analyses are inconclusive. The test is intended as an occasional second-line adjunct (for example, when cyst cytology, cyst fluid CEA, or imaging remain indeterminate and testing is expected to influence management). Regulatory oversight: PathFinderTG is performed as a laboratory-developed test under CLIA for high-complexity testing; to date the FDA has not required review. Documentation and prior authorization requirements apply when coverage criteria are used.
Definitions
Evidence & Regulatory Note
| LCD Name | LCD Number | Type | Effective Date | Note |
|---|---|---|---|---|
| Local Coverage Determination: Loss-of-Heterozygosity Based Topographic Genotyping with PathfinderTG | LCD | Details not provided in source for blank fields (number and effective date). |
Last review
Policy effective
Documentation must be maintained in the medical record per policy.
Commercial Products - Contract exclusions
Coverage may be restricted by specific group contract exclusions and state or employer mandates:
ANY of the following
Refer to the member's benefit booklet and Coding section for specific exclusions and authorization requirements.
Use of unlisted CPT/HCPCS codes
There is no established CPT or HCPCS code which adequately describes the procedure; therefore, report the service using an unlisted CPT code (84999 or 81479).